ZIOP - ZIOPHARM Oncology, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.2800
+0.1400 (+3.38%)
As of 12:14PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.1400
Open4.1700
Bid4.2600 x 1100
Ask4.2700 x 800
Day's Range4.1200 - 4.2875
52 Week Range1.5600 - 7.2500
Volume367,339
Avg. Volume1,789,752
Market Cap771.924M
Beta (3Y Monthly)3.18
PE Ratio (TTM)4.44
EPS (TTM)0.9640
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.29
Trade prices are not sourced from all markets
  • MoneyShow

    Ziopharm Tests "Sleeping Beauty" for Oncology Treatment

    Ziopharm Oncology (ZIOP) recently announced that the FDA has cleared an investigational new drug application (IND) for a Phase I trial to test their 3rd generation CD19-specific CAR-T, explains biotech sector specialist John McCamant, editor of The Medical Technology Stock Letter.

  • GlobeNewswire

    Ziopharm Oncology Names Drug Development Leader Dr. Chris Bowden to Board of Directors

    Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP), today announced that Chris Bowden, M.D., an oncology drug development executive with more than 20 years leadership experience spanning pre-clinical development through commercialization, including the approval of several cancer medicines, has been appointed to the Company’s Board of Directors.  Dr. Bowden is the Chief Medical Officer of Agios Pharmaceuticals and was previously Vice President, Product Development Oncology, at Genentech, Inc., a member of the Roche Group. “We are delighted to welcome Dr. Bowden to the Ziopharm Board.

  • Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment
    Zacks

    Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment

    Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.

  • GlobeNewswire

    Ziopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T

    Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application (IND) for a phase 1 clinical trial to evaluate CD19-specific CAR-T, produced using a process termed rapid personalized manufacture (RPM), as an investigational treatment for patients with relapsed CD19+ leukemias and lymphomas. The IND clearance builds upon the Company’s experience with two prior generations of immunotherapy trials using the Sleeping Beauty platform, which it believes is the most clinically-advanced non-viral approach to the genetic modification of T cells.

  • MDNA.TO: Increased Overall Survival in rGBM Patients Seen with High Dose MDNA55…
    Zacks Small Cap Research

    MDNA.TO: Increased Overall Survival in rGBM Patients Seen with High Dose MDNA55…

    By David Bautz, PhD TSX:MDNA.TO READ THE FULL MDNA.TO RESEARCH REPORT Business Update Updated Data from Phase 2b Trial Presented at Targeting Innate Immunity Congress On September 25, 2019, Medicenna Therapeutics Corp. (TSX:MDNA) announced the presentation of updated clinical data from the ongoing Phase 2b trial of MDNA55, an IL-4 targeted toxin,

  • GlobeNewswire

    Ziopharm Oncology to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

    BOSTON, Aug. 28, 2019 -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, will participate in a.

  • GlobeNewswire

    Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares of Ziopharm’s common stock effective August 19, 2019. The options were granted as an inducement material to such employee’s entering into employment with Ziopharm in accordance with Nasdaq Listing Rule 5635(c)(4). The option has an exercise price of $5.18 per share, the closing price of the Company’s common stock on August 19, 2019.

  • Thomson Reuters StreetEvents

    Edited Transcript of ZIOP earnings conference call or presentation 8-Aug-19 12:30pm GMT

    Q2 2019 ZIOPHARM Oncology Inc Earnings Call

  • GlobeNewswire

    Ziopharm Oncology Announces Publication of Positive Results of Phase 1 Monotherapy Trial of Controlled IL-12 in Patients with Recurrent Glioblastoma in Science Translational Medicine

    Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP), today announced the publication of its phase 1 trial of Controlled IL-12 in patients with recurrent glioma in the journal Science Translational Medicine. The publication entitled, “Regulatable interleukin 12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial” can be accessed at https://stm.sciencemag.org/.

  • ZIOPHARM Oncology, Inc. (ZIOP) Q2 2019 Earnings Call Transcript
    Motley Fool

    ZIOPHARM Oncology, Inc. (ZIOP) Q2 2019 Earnings Call Transcript

    ZIOP earnings call for the period ending June 30, 2019.

  • GlobeNewswire

    Ziopharm Oncology Reports Second Quarter 2019 Financial Results

    Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP), a clinical stage immuno-oncology company developing next generation cell and gene therapies, today announced its financial results for the second quarter ended June 30, 2019, and provided an update on the Company’s recent activities. “We have made significant advancements in our programs during the second quarter.

  • GlobeNewswire

    Ziopharm Oncology Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Glioma

    Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP), today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion recommending Ad-RTS-hIL-12 plus veledimex (Controlled IL-12) for designation as an orphan medicinal product for the treatment of glioma. “Malignant glioma is an aggressive and life-threatening cancer with few treatment options,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm.

  • GlobeNewswire

    Ziopharm Oncology to Host Conference Call to Discuss Second Quarter 2019 Results on August 8, 2019

    BOSTON, July 30, 2019 -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, August 8, at 8:30 a.m. ET to.

  • GlobeNewswire

    Ziopharm Oncology Announces $45 Million Warrant Exercise by Existing Shareholders in a Private Placement

    Ziopharm Oncology, Inc. (“Ziopharm”) (ZIOP), today announced that it has entered into an agreement with existing investors for the exercise of previously issued warrants to purchase common stock in a private placement that is expected to result in gross proceeds to Ziopharm of approximately $45 million, before deducting placement agent and other offering expenses. Pursuant to the terms of the securities issuance agreement, at the closing of the private placement, the investors have agreed to exercise their warrants for an aggregate of 15,015,152 shares of common stock, at an exercise price of $3.01 per share.

  • MoneyShow

    Ziopharm Attracts Top Talent from the National Cancer Institute

    In a major coup for Ziopharm Oncology (ZIOP), the company has attracted the services of Drew Deniger, Ph.D., from the National Cancer Institute (NCI) to lead the company's program to genetically modify T-cells to express neoantigen-specific T-cell receptors (TCRs), effective July 29, 2019, explains John McCamant, editor of The Medical Technology Stock Letter.

  • GlobeNewswire

    Ziopharm Oncology Names Sath Shukla as Chief Financial Officer

    Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP), a clinical stage immuno-oncology company developing next-generation cell and gene therapies, today announced that Satyavrat “Sath” Shukla, CFA, has been appointed as the Company’s Chief Financial Officer. Mr. Shukla joins with 20 years of strategic corporate and financial leadership experience.

  • GlobeNewswire

    Ziopharm Oncology Names NCI’s Dr. Drew Deniger to Direct TCR-T Cell Therapy Program

    BOSTON, July 03, 2019 -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced Drew Deniger, Ph.D., will join Ziopharm from the National Cancer.

  • GlobeNewswire

    Ziopharm Oncology Initiates Phase 2 Trial Evaluating Combination Therapy of Controlled IL-12 with Libtayo® (cemiplimab-rwlc) to Treat Patients with Recurrent Glioblastoma

    Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP) today announced the initiation of a phase 2 clinical trial evaluating Controlled IL-12 (Ad-RTS-hIL-12 plus veledimex, Ad+V), in combination with PD-1 antibody Libtayo® (cemiplimab-rwlc) for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults. “We piloted the combination of interleukin-12 (IL-12) and a PD-1-specific antibody in a phase 1 trial which lays the foundation for recruitment to this phase 2 study for patients with rGBM. This trial seeks to further IL-12, which activates the patient’s own immune system to attack cancer, by coupling with the inhibition of PD-1 to enhance the effectiveness of the combination,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm.

  • GlobeNewswire

    Ziopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo® (nivolumab) Phase 1 Combination Trial in Brain Cancer

    Investigators from this multi-center trial, conducted at Northwestern University in Chicago, Brigham and Women’s Hospital in Boston, and The University of Texas MD Anderson Cancer Center in Houston, have indicated interest in expanding the study and the Company now expects to enroll additional patients at the highest dosing level, subject to final agreement by the Data and Safety Monitoring Board. “We are pleased to complete enrollment of the dose escalation of Ad-RTS-hIL-12 + veledimex and nivolumab and explore the potential to expand this combination trial to further enrich our clinical experience,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm.

  • ZIOPHARM Oncology (NASDAQ:ZIOP) Shareholders Have Enjoyed A 21% Share Price Gain
    Simply Wall St.

    ZIOPHARM Oncology (NASDAQ:ZIOP) Shareholders Have Enjoyed A 21% Share Price Gain

    Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...

  • GlobeNewswire

    Ziopharm Oncology Appoints Heidi Hagen to Board of Directors

    Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP), today announced Heidi Hagen, an experienced and entrepreneurial biotechnology operations executive, has been appointed to the Company’s Board of Directors effective immediately.

  • GlobeNewswire

    Ziopharm Oncology Announces FDA Clearance of IND for Sleeping Beauty TCR-T Cell Therapy Trial at NCI

    Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (ZIOP) announced that the investigational new drug (IND) application submitted by the National Cancer Institute (NCI) has received clearance from the U.S. Food and Drug Administration (FDA) for a clinical trial in solid tumors to evaluate T-cell receptor (TCR) T-cell therapy utilizing Ziopharm’s Sleeping Beauty platform. “This study is the result of extensive work by Dr. Steven Rosenberg and his team at the NCI, including Dr. Drew Deniger, to harness our Sleeping Beauty non-viral gene transfer technology to express neoantigen-specific T-cell receptors (TCRs),” said Dr. Laurence Cooper, Chief Executive Officer of Ziopharm.

  • GlobeNewswire

    Ziopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual Meeting

    BOSTON, June 02, 2019 (GLOBE NEWSWIRE) --  Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (ZIOP), a clinical stage immuno-oncology company developing next-generation cell and gene therapies, today announced the presentation of new interim analyses of clinical data from two ongoing substudies in its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination with a PD-1 inhibitor, for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults, at the American Society for Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31 to June 4, 2019. “Profiling an expanded number of patients with rGBM shows that Controlled IL-12 engages patients’ immune systems which we previously showed was an indicator of improved overall survival,” said Laurence Cooper, M.D., Ph.D., CEO of Ziopharm.

  • Benzinga

    The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 28) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Arrowhead ...